Gianella Pietro, Glatz Nicolas, Berra Gregory, Janssens Jean-Paul
Service de pneumologie, Département des spécialités de médecine, HUG, 1211 Genève 14.
Rev Med Suisse. 2017 Jan 11;13(544-545):96-101.
We chose, for this update on novelties in treatments for pulmonary disorders in 2016, to focus on advances in 3 pulmonary disorders : chronic obstructive pulmonary disease (COPD), asthma and IPF. For COPD, the contribution of inhaled glucocorticosteroids and roflumilast are revisited and the benefits obtained through endoscopic volume reduction procedures are clarified. In asthma and IPF, new molecules offer new hopes : a bettre control of exacerbations in asthma and a stabilisation or slowing of disease progression in IPF.
在本次2016年肺部疾病治疗新进展的更新中,我们选择聚焦于三种肺部疾病的进展:慢性阻塞性肺疾病(COPD)、哮喘和特发性肺纤维化(IPF)。对于COPD,重新审视了吸入性糖皮质激素和罗氟司特的作用,并阐明了通过内镜减容手术获得的益处。在哮喘和IPF方面,新分子带来了新希望:更好地控制哮喘发作,以及稳定或延缓IPF的疾病进展。